ReviewPneumonia (Nathan Qld.)2025
Corticosteroids and hospital-acquired pneumonia.
Review in Pneumonia (Nathan Qld.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Hospital-acquired pneumonia (HAP) is a serious infection with high mortality rates, especially in critically ill patients. The role of corticosteroids as adjunctive therapy in this population is debated. These agents have anti-inflammatory and immunomodulatory properties, which have the potential to reduce pulmonary inflammation and improve oxygenation. However, the risk of secondary infections and metabolic complications that their use may entail is a matter for concern, given their impact on patients’ outcome. In this review, we discuss the current scientific evidence on the use of corticosteroids as adjunctive therapy for patients with HAP and VAP, its implications for patients’ clinical outcomes, and the possible effects. Corticosteroids are not recommended as standard therapy for HAP/VAP but may be beneficial in selected subgroups of patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.